C9460: Injection, cangrelor, 1 mg
C9460 is a HCPCS Level II code for injection, cangrelor, 1 mg. It belongs to the Outpatient Prospective Payment System section. Whether Medicare pays it depends on the coverage rule below.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q4-Oct. This states Medicare’s position on the code, not on your particular claim.
Medically Unlikely Edits: units per day
The most units of C9460 Medicare will pay on one date of service. Bill more on a single line and it is denied. The limit is not the same in every setting, so the row that matters is the one matching the claim you are building.
- practitioner
- 1 unit MAI 3: Date of Service Edit: Clinical · Clinical: CMS Workgroup
- outpatient
- 100 units MAI 3: Date of Service Edit: Clinical · Prescribing Information
The adjudication indicator decides whether exceeding the limit is worth appealing at all: MAI 1 is a line edit you can support with documentation, MAI 3 is a date-of-service edit that is also appealable, and MAI 2 is absolute, no documentation overrides it. CMS MUE 2026Q4.
The CMS record for C9460
- Long descriptor
- Injection, cangrelor, 1 mg
- Short descriptor
- Injection, cangrelor
- Added
- January 1, 2016
- BETOS
- O1E
- Pricing indicator
- 53: Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
Berenson-Eggers Type of Service: CMS's own analytic grouping.
Statute.
Codes adjacent to C9460
HCPCS has no hierarchy: related items simply sit next to each other in the numbering. If C9460 is not quite right, the correct code is very often within a few positions of it.
- C9452Injection, ceftolozane 50 mg and tazobactam 25 mgterminated
- C9453Injection, nivolumab, 1 mgterminated
- C9454Injection, pasireotide long acting, 1 mgterminated
- C9455Injection, siltuximab, 10 mgterminated
- C9456Injection, isavuconazonium sulfate, 1 mgterminated
- C9457Injection, sulfur hexafluoride lipid microsphere, per mlterminated
- C9458Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuriesterminated
- C9459Flutemetamol f18, diagnostic, per study dose, up to 5 millicuriesterminated
- C9461Choline c 11, diagnostic, per study doseterminated
- C9462Injection, delafloxacin, 1 mgterminated
- C9463Injection, aprepitant, 1 mgterminated
- C9464Injection, rolapitant, 0.5 mgterminated
- C9465Hyaluronan or derivative, durolane, for intra-articular injection, per doseterminated
- C9466Injection, benralizumab, 1 mgterminated
- C9467Injection, rituximab and hyaluronidase, 10 mgterminated
- C9468Injection, factor ix (antihemophilic factor, recombinant), glycopegylated, rebinyn, 1 i.u.terminated